Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Columbia Labs

This article was originally published in The Tan Sheet

Executive Summary

Signs letter-of-intent agreement giving Lake Pharmaceutical exclusive U.S. rights to market Advantage 24, a nonoxynol-9 sustained-release contraceptive gel using Columbia's bioadhesive technology. Advantage 24 is set to be launched by September and expected to be in "close to 40,000 outlets by the end of 1995," Columbia said. Safety trials by the World Health Organization have been completed on the use of Advantage 24 in preventing transmission of STDs; WHO is expected to begin efficacy trials soon ("The Tan Sheet" April 11, p. 11)
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel